News

Pregnant women with disabilities have a much higher risk for severe pregnancy- and birth-related complications and death than other pregnant women, according to findings by researchers at the National Institutes of Health. Appearing in JAMA Network Open, the analysis of more than 223,000 deliveries in 19 U.S. hospitals found that roughly 2,199 women had a disability.

It just got easier to participate in the PregSource®: Crowdsourcing to Understand Pregnancy research project. The free app allows participants to track their weight, sleep, mood, and other features of their pregnancy in just a few taps.

Awarded projects seek to reduce pregnancy complications and prevent maternal deaths.

Dr. Grewal has been acting director of the division since February 2020.

The National Institutes of Health will support a four-year follow-up study on the potential long-term effects of COVID-19 on women infected with SARS-CoV-2 during pregnancy. The study will also follow their offspring for any potential long-term effects.

As we usher in November and Thanksgiving, it’s a fitting time to reflect on NICHD’s commitment to research on nutrition.

Episodes of maternal stress or depression during pregnancy are associated with chemical modifications to placental genes, according to a study by researchers from the National Institutes of Health. The modifications involve DNA methylation—binding of compounds known as methyl groups to DNA—which can alter a gene’s activity. Some of the methylation changes associated with maternal depression occurred near genes involved in brain development, suggesting that maternal depression in pregnancy could have long-term implications for the mental development of the child.

No serious adverse events were reported by 180 breastfeeding women receiving either the Pfizer or Moderna vaccine, either among themselves or in their infants, according to a study funded by the National Institutes of Health. For the mothers, adverse events included muscle and body aches, fever and vomiting, pain, redness, swelling, or itching at the injection site.

NIH-supported program reduces maternal deaths, complications in rural Guatemalan communities.

Racial and ethnic disparities in maternal mortality in the United States may be larger than previously reported, suggests an NICHD-funded study.

Preemptive treatment for a nonviable pregnancy of unknown location resolves the condition more rapidly than treating symptoms as they arise, suggests an NICHD-supported study. However, both treatment approaches convey similar risks of adverse events.

Preeclampsia—a life-threatening hypertensive disorder of pregnancy—may begin with a failure of the outermost cells of the early placenta to sufficiently invade the uterine wall, suggests a study funded by the National Institutes of Health. Researchers generated these outermost cells—known as trophoblasts—from stem cells taken from placentas of women who had preeclampsia during pregnancy.

Among American Black and white women, the risk and extent of fibroids—benign tumors of the uterus—are associated with ancestry to distinct regions and populations, suggests a study funded by the National Institutes of Health. The study provides information that may lead to insights on the origins and treatments for these common tumors.

The National Institutes of Health will award up to $400,000 to individuals or groups who design an effective method for analyzing a large data set of first-time pregnancies and identifying risk factors for adverse outcomes, such as hypertensive disorders, diabetes and infection. A total of $50,000 will be awarded to each of seven winners designing the most effective means to analyze the data. An additional $10,000 will be awarded to the top five winners whose methods identify risk factors in disadvantaged populations.

Researchers at the National Institutes of Health have developed a prototype device that could potentially diagnose pregnancy complications by monitoring the oxygen level of the placenta.

A healthy diet around the time of conception through the second trimester may reduce the risk of several common pregnancy complications, suggests a study by researchers at the National Institutes of Health.

NICHD Director Dr. Diana Bianchi is joined by NIH Office of Research on Women’s Health Director Dr. Janine Clayton in assessing the growing maternal health crisis in the United States and describing NIH’s efforts to address it.

Current vaccines to prevent COVID-19 are highly effective in producing antibodies in pregnant women, resulting in more antibodies than what is generated from a natural SARS-CoV-2 virus infection, according to a study funded by the National Institutes of Health. Moreover, antibodies produced after vaccination are present in breastmilk and travel across the placenta, indicating that vaccination during pregnancy will also confer immunity to newborns.

For many COVID-19 patients, full recovery remains elusive even long after they should feel “better.” NIH recently announced research opportunities to understand COVID-19 long haulers, who have what researchers now refer to as Post-acute sequelae of SARS-CoV-2 infection (PASC). NICHD joins these opportunities while remaining focused on PASC patients within our audiences of interest—pregnant and lactating people, children, and those with disabilities.

A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.